Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic Acid in Residual Chronic Subdural Hematoma
NCT03280212Phase 3Unknown
- Sponsor
- Unity Health Toronto
- Start
- Mar 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tranexamic acid in chronic subdural hematoma (CSDH), sponsored by Unity Health Toronto. Status: unknown.
02
Drugs
tranexamic acid
03
Conditions
chronic subdural hematoma (CSDH)
Beyond the preview
Go deeper on NCT03280212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03280212.